Literature DB >> 17570767

A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses.

Da-Hai Yu1, Xi-Dan Hu, Hong Cai.   

Abstract

We constructed a combined DNA vaccine comprising genes encoding the antigens BCSP31, superoxide dismutase (SOD), and L7/L12 and evaluated its immunogenicity and protective efficacy. Immunization of mice with the combined DNA vaccine offered high protection against Brucella abortus (B. abortus) infection. The vaccine induced a vigorous specific immunoglobulin G (IgG) response, with higher IgG2a than IgG1 titers. Cytokine profiling performed at the same time showed a biased Th1-type immune response with significantly increased interferon-gamma and tumor necrosis factor-alpha stimulation. CD8(+), but not CD4(+), T cells accumulated at significantly higher levels after administration of the vaccine. Granzyme B-producing CD8(+) T cells were significantly higher in number in samples prepared from combined DNA-vaccinated mice compared with S19-vaccinated mice, demonstrating that the cytotoxicity lysis pathway is involved in the response to Brucella infection. The success of our combined DNA vaccine in a mouse model suggests its potential efficacy against brucellosis infection in large animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570767     DOI: 10.1089/dna.2006.0552

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  13 in total

1.  TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro.

Authors:  Jia-Yun Li; Yuan Liu; Xiao-Xue Gao; Xiang Gao; Hong Cai
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

2.  The rLrp of Mycobacterium tuberculosis inhibits proinflammatory cytokine production and downregulates APC function in mouse macrophages via a TLR2-mediated PI3K/Akt pathway activation-dependent mechanism.

Authors:  Yuan Liu; Jia-Yun Li; Su-Ting Chen; Hai-Rong Huang; Hong Cai
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

3.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 4.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 6.  Recent advances in Brucella abortus vaccines.

Authors:  Elaine M S Dorneles; Nammalwar Sriranganathan; Andrey P Lage
Journal:  Vet Res       Date:  2015-07-08       Impact factor: 3.683

7.  Immune Response of Calves Vaccinated with Brucella abortus S19 or RB51 and Revaccinated with RB51.

Authors:  Elaine M S Dorneles; Graciela K Lima; Andréa Teixeira-Carvalho; Márcio S S Araújo; Olindo A Martins-Filho; Nammalwar Sriranganathan; Hamzeh Al Qublan; Marcos B Heinemann; Andrey P Lage
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

8.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

9.  Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and B. ovis: Comparing Cell-Mediated and Protective Immune Responses Elicited by pCDNA3.1 and pVAX1 DNA Vaccines Coding for Omp31 of Brucella melitensis.

Authors:  Naser Harzandi; Haniyeh Aghababa; Nima Khoramabadi; Termeh Tabaraie
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

Review 10.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.